Rhu-pGSN for Acute Respiratory Distress Syndrome (ARDS) (NCT05947955)
A Phase 2 Randomized Double-blind Placebo-controlled Study To Evaluate The Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard Care For Moderate-to-Severe ARDS Due To Pneumonia Or Other Infections
🩺 Plain-English Summary (8th-Grade Level)
BTI-203 is a randomized, double-blind, placebo-controlled, multicenter, Phase 2 proof-of-concept (POC) study to evaluate the efficacy and safety of rhu-pGSN plus standard of care (SOC) in subjects with moderate-to-severe ARDS (P/F ratio ≤150) due to pneumonia or other infections. Potential subjects hospitalized with pneumonia or other infections are to be screened within 24 hours of diagnosis of ARDS.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Medical Center — Los Angeles, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (70 Sites)
Showing the first 25 of 70 sites.
- Cedars-Sinai Medical Center — Los Angeles, California
- Wellstar MCG Augusta University — Augusta, Georgia
- Northwestern University - Pulmonary and Critical Care Medicine — Chicago, Illinois
- University of Louisville Hospital - Jewish Hospital — Louisville, Kentucky
- University of Louisville-Jewish Hospital — Louisville, Kentucky
- Mayo Clinic — Rochester, Minnesota
- Hannibal Regional Hospital — Hannibal, Missouri
- Bryan Medical Center — Lincoln, Nebraska
- New York University Grossman School of Medicine — New York, New York
- Penn State Health - Milton S. Hershey Medical Center — Hershey, Pennsylvania
- Penn State Health - Milton S. Hershey Medical Center — Hershey, Pennsylvania
- University of Pittsburgh Medical Center — Pittsburgh, Pennsylvania
- McGovern Medical School - UT Physicians Pulmonary Medicine - Texas Medical Center — Houston, Texas
- Baylor Scott & White Health — Temple, Texas
- HUB - Hôpital Erasme — Brussels,
- CHU Charleroi Marie Curie Hospital — Charleroi,
- Centre Hospitalier Regional de la Citadelle — Liège,
- Clinique Saint-Pierre Ottignies — Ottignies,
- UMHAT "Alexandrovska" EAD — Sofia,
- Foothills Medical Centre — Calgary, Alberta
- Grey Nuns Hospital — Edmonton, Alberta
- Lions Gate Hospital — North Vancouver, British Columbia
- Sunnybrook Health Sciences Centre — Toronto, Ontario
- University Health Network (UHN)-Toronto General Hospital (TGH) — Toronto, Ontario
- McGill University Health Centre - Royal Victoria Hospital (MUHC-RVH) — Montreal, Quebec
📞 Contact the Study Coordinator
Phone: (848) 992-5888
Email: hlevy@hlevyconsulting.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Respiratory Distress Syndrome
- Identification and Treatment of Hypoxemic Respiratory Failure and ARDS With Protection, Paralysis, and Proning Pathway — Calgary, Alberta
- Molecular Epidemiology of Acute Respiratory Distress Syndrome (ARDS) — Boston, Massachusetts
- ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND) — Birmingham, Alabama
- Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome — Tucson, Arizona
- Macrophage Programing in Acute Lung Injury: MiniBAL — Denver, Colorado
- Vascular ARDS Recruitment After Inhaled Nitric Oxide — Boston, Massachusetts
Explore by condition: All Acute Respiratory Distress Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.